Hoseok I

Prof. Hoseok I

Pusan National University, Busan, Republic of Korea
+1
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015
Verified
Book Chapter
Closed access
HIHoseok I
Hoseok I
JCJe-Yoel Cho
Je-Yoel Cho

1 December 2016 in Journal of Thoracic Oncology
Verified
Journal Article
Open access
SLShiyong Li
Shiyong Li
YCYoon-La Choi
Yoon-La Choi
ZGZhuolin Gong
Zhuolin Gong
XLXiao Liu
Xiao Liu
MLMaruja Lira
Maruja Lira
MMMao Mao
Mao Mao
The incidence rate of lung adenocarcinoma (LUAD), the predominant histological subtype of lung cancer, is elevated in Asians, particularly in female nonsmokers. The mutation patterns in LUAD in Asians might be distinct from those in LUAD in whites. We profiled 271 resected LUAD tumors (mainly stage I) to characterize the genomic landscape of LUAD in Asians with a focus on female nonsmokers. Mutations in EGFR, KRAS, erb-b2 receptor tyrosine kinase 2 gene (ERBB2), and BRAF; gene fusions involving anaplastic lymphoma receptor tyrosine kinase gene (ALK), ROS1, and ret proto-oncogene (RET); and Met Proto-Oncogene Tyrosine Kinase (MET) exon 14 skipping were the major drivers in LUAD in Asians, exhibiting mutually exclusive and differing prevalence from those reported in studies of LUAD in non-Asians. In addition, we identified a novel mutational signature of XNX (the mutated base N in the middle flanked by two identical bases at the 5' and 3' positions) that was overrepresented in LUAD tumors in nonsmokers and negatively correlated with the overall mutational frequency. In this cohort, approximately 85% of individuals have known driver mutations (EGFR 59.4%, KRAS 7.4%, ALK 7.4%, ERBB2 2.6%, ROS1 2.2%, RET 2.2%, MET 1.8%, BRAF 1.1%, and NRAS 0.4%). Seventy percent of smokers and 90% of nonsmokers had defined oncogenic drivers matching the U.S. Food and Drug Administration-approved targeted therapies.

27 May 2014 in Journal of Nuclear Medicine
Verified
Journal Article
Closed access
GLGeewon Lee
Geewon Lee
HIHoseok I
Hoseok I
SKSeong-Jang Kim
Seong-Jang Kim
YJYeon Joo Jeong
Yeon Joo Jeong
IKIn Joo Kim
In Joo Kim
GKGwang Ha Kim
Gwang Ha Kim
This was a study to compare the diagnostic efficacies of endoscopic ultrasonography (EUS), CT, PET/MR imaging, and PET/CT for the preoperative local and regional staging of esophageal cancer, with postoperative pathologic stage used as the reference standard. During 1 y, 19 patients with resectable esophageal cancer were enrolled and underwent preoperative EUS, CT, PET/CT, and PET/MR imaging. A chest radiologist and nuclear medicine physician retrospectively reviewed the images and assigned tumor and lymph node stages according to the seventh version of the TNM system and the American Joint Committee on Cancer staging system. Four patients who were treated nonsurgically were excluded from data analysis. The efficacies of EUS, CT, PET/CT, and PET/MR imaging were compared. Primary tumors were correctly staged in 13 (86.7%), 10 (66.7%), and 5 (33.3%) patients at EUS, PET/MR imaging, and CT, respectively (P value ranging from 0.021 to 0.375). The accuracy of determining T1 lesions was 86.7%, 80.0%, and 46.7% for EUS, PET/MR imaging, and CT, respectively. For distinguishing T3 lesions, the accuracy was 93.3% for EUS and 86.7% for both PET/MR imaging and CT. For lymph node staging, the accuracy was 83.3%, 75.0%, 66.7%, and 50.0% for PET/MR imaging, EUS, PET/CT, and CT, respectively. In addition, area-under-the-curve values were 0.800, 0.700, 0.629, and 0.543 for PET/MR imaging, EUS, PET/CT, and CT, respectively. PET/MR imaging demonstrated acceptable accuracy for T staging compared with EUS and, although not statistically significant, even higher accuracy than EUS and PET/CT for prediction of N staging. With adjustments in protocols, PET/MR imaging may provide an important role in preoperative esophageal cancer staging in the future.

1 January 2015 in Annals of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
CKChang Wan Kim
Chang Wan Kim
DKDo Hyung Kim
Do Hyung Kim
BSBong Soo Son
Bong Soo Son
JCJeong Su Cho
Jeong Su Cho
YKYeong Dae Kim
Yeong Dae Kim
HAHyo Yeong Ahn
Hyo Yeong Ahn
Extracorporeal membrane oxygenation (ECMO) is widely used to treat respiratory distress during cardiac or respiratory arrest; moreover, its use is being extended to a wide variety of clinical fields. In this study we assess the utility of ECMO in the management of airway obstruction. 15 patients underwent ECMO for airway obstruction. We retrospectively analyzed and evaluated the feasibility of ECMO in the treatment of airway problems. Seven patients received ECMO to facilitate respiration and promote stability during trachea surgery. In six cases ECMO ceased immediately following the operation; in the remaining case ECMO cessation was delayed due to post-operative ARDS. In three cases emergency ECMO was used in response to respiratory arrest; two patients died. In five cases ECMO was emergently inserted to prevent death, following airway blockade by massive hemoptysis. One patient was not discharged from the intensive care unit. Another patient was transferred to a general ward but died from other causes. ECMO is useful during anesthesia in patients at high risk of airway blockade, for example due to endobronchial bleeding, and during complex thoracic surgery. ECMO confers a safer environment during airway surgery, and its complication rate is acceptable.

1 May 2011 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
JCJeong Su Cho
Jeong Su Cho
YKYeong Dae Kim
Yeong Dae Kim
JKJong Won Kim
Jong Won Kim
HIHoseok I
Hoseok I
MKMin Su Kim
Min Su Kim

1 May 2006 in European Journal of Cancer
Verified
Journal Article
Closed access
PDF file
ELEun Ju Lee
Eun Ju Lee
BLBo Bin Lee
Bo Bin Lee
JKJin Wook Kim
Jin Wook Kim
YSYoung Mog Shim
Young Mog Shim
HIHoseok I
Hoseok I
KDKim Duk-Hwan
Kim Duk-Hwan